Antibodies
9 April 2008
Phase II Study of IMC-A12 for Advanced Head and Neck Cancer Commences Patient Enrollment9 April 2008
CuraGen Advances CR011-vcMMAE into Phase II8 April 2008
Amgen Statement on Romiplostim PDUFA Date1 April 2008
Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma31 March 2008
Phase II results for CDP791 in non-small cell lung cancer support further clinical development31 March 2008
Crucell Announces Start of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US28 March 2008
Seattle Genetics Expands SGN-35 Clinical Program with Initiation of Second Phase I Trial27 March 2008
Thallion provides update on Shigamabs (R) program26 March 2008
DAIICHI SANKYO Extends Alliance with MorphoSys for Use of HuCAL GOLD to Develop Novel Antibody Therapies20 March 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers20 March 2008
CHMP Upholds Negative Opinion for the EU Application for Cimzia® in the Treatment of Crohn’s Disease20 March 2008
Seattle Genetics Initiates SGN-33 Clinical Trial in Combination with Revlimid(R) for Myelodysplastic Syndromes (MDS)20 March 2008
Zevalin(R) Receives Positive CHMP Opinion in Europe for First-Line Consolidation Treatment19 March 2008
MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma17 March 2008
MorphoSys Obtains Agreement for Production of Antibody Material in MOR202 Program with Crucell and DSM13 March 2008
Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports